文献速递临床试验与 GCP流行病学与生物统计

应用复发风险预测模型指导静脉血栓栓塞抗凝疗程的随机对照试验

Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2020-06-26

该随机对照试验纳入883例无诱因静脉血栓栓塞患者,比较维也纳预测模型(VPM)指导抗凝时长决策与常规诊疗对24个月复发风险的影响。结果显示两组复发风险无显著差异(RR 0.92,95%CI 0.63-1.35,p=0.67),VPM区分度良好(c-statistic 0.76),低预测风险患者实际复发率亦低。

要点

  • VPM指导抗凝决策未降低无诱因VTE患者24个月总体复发风险。
  • VPM区分度良好(c-statistic 0.76),低预测风险者实际复发率低。
  • 低预测风险患者或可安全停用抗凝,但需进一步验证。

核心结论

  • 在全部无诱因VTE患者中应用VPM不太可能降低总体复发风险。
  • 低预测复发风险患者的实际复发率亦低,提示停用抗凝可能安全。

研究设计与样本

  • 随机对照试验,VPM指导决策组441例,常规诊疗组442例。
  • 纳入荷兰9个血栓服务点的无诱因VTE患者,随访24个月。
  • 主要结局为24个月内复发性VTE,次要结局包括大出血和临床相关非大出血。

主要发现

  • 总人群883例,平均年龄55岁,男性507例(57.4%)。
  • 复发VTE共96例(10.9%),干预组46例 vs 对照组50例(RR 0.92,95%CI 0.63-1.35,p=0.67)。
  • 大出血共4例,每组各2例;临床相关非大出血共20例(干预组12例 vs 对照组8例)。
  • VPM区分度良好(c-statistic 0.76,95%CI 0.69-0.83),校准度中等至良好。
  • 预测风险>2%至4%的284例患者中,实际复发率为2.5%(95%CI 0.7%-4.3%)。

关键数值与推荐

  • VPM区分度c-statistic 0.76(95%CI 0.69-0.83)。
  • 预测风险>2%至4%者实际复发率2.5%(95%CI 0.7%-4.3%)。

临床怎么用

  • VPM可用于评估无诱因VTE患者复发风险以辅助抗凝时长决策。
  • 对VPM预测低风险患者,停用抗凝可能是合理选择。
  • VPM指导决策未显示总体复发风险降低,不应推广至所有患者。

局限性

  • 因招募率下降,未达到每臂750例的预设样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with unprovoked (i.e., without the presence of apparent transient risk factors such as recent surgery) venous thromboembolism (VTE) are at risk of recurrence if anticoagulants are stopped after 3-6 months, yet their risk remains heterogeneous. Thus, prolonging anticoagulant treatment should be considered in high-risk patients, whereas stopping is likely preferred in those with a low predicted risk. The Vienna Prediction Model (VPM) could aid clinicians in estimating this risk, yet its clinical effects and external validity are currently unknown. The aim of this study was to investigate the clinical impact of this model on reducing recurrence risk in patients with unprovoked VTE, compared to usual care. METHODS AND FINDINGS: In a randomized controlled trial, the decision to prolong or stop anticoagulant treatment was guided by predicted recurrence risk using the VPM (n = 441), which was compared with usual care (n = 442). Patients with unprovoked VTE were recruited from local thrombosis services in the Netherlands (in Utrecht, Harderwijk, Ede, Amersfoort, Zwolle, Hilversum, Rotterdam, Deventer, and Enschede) between 22 July 2011 and 30 November 2015, with 24-month follow-up complete for all patients by early 2018. The primary outcome was recurrent VTE during 24 months of follow-up. Secondary outcomes included major bleeding and clinically relevant non-major (CRNM) bleeding. In the total study population of 883 patients, mean age was 55 years, and 507 (57.4%) were men. A total of 96 recurrent VTE events (10.9%) were observed, 46 in the intervention arm and 50 in the control arm (risk ratio 0.92, 95% CI 0.63-1.35, p = 0.67). Major bleeding occurred in 4 patients, 2 in each treatment arm, whereas CRNM bleeding occurred in 20 patients (12 in intervention arm versus 8 in control arm). The VPM showed good discriminative power (c-statistic 0.76, 95% CI 0.69-0.83) and moderate to good calibration, notably at the lower spectrum of predicted risk. For instance, in 284 patients with a predicted risk of >2% to 4%, the observed rate of recurrence was 2.5% (95% CI 0.7% to 4.3%). The main limitation of this study is that it did not enroll the preplanned number of 750 patients in each study arm due to declining recruitment rate. CONCLUSIONS: Our results show that application of the VPM in all patients with unprovoked VTE is unlikely to reduce overall recurrence risk. Yet, in those with a low predicted risk of recurrence, the observed rate was also low, suggesting that it might be safe to stop anticoagulant treatment in these patients. TRIAL REGISTRATION: Netherlands Trial Register NTR2680.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Geersing GJ, Hendriksen JMT, Zuithoff NPA, et al. Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial. PLoS Med. 2020. PMID: 32589630. doi:10.1371/journal.pmed.1003142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。